Distinct cardiac transcriptional profiles defining pregnancy and exercise

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Chung, Eunhee ^a   Heimiller, Joseph ^a   Leinwand, Leslie A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOCHROME P450; PROTEASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIESTRUS; EXERCISE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; HEART HYPERTROPHY; METABOLIC REGULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREGNANCY; PROTEIN FUNCTION; PUERPERIUM; SECOND TRIMESTER PREGNANCY; SIGNAL TRANSDUCTION; THIRD TRIMESTER PREGNANCY; TRANSCRIPTION REGULATION;

ANIMALS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHYSICAL CONDITIONING, ANIMAL; PREGNANCY; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

ANIMALIA; MUS;

EID: 84864443767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042297     Document Type: Article

References (72)

1. Frey N, Olson EN, (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65: 45-79.
2. McMullen JR, Jennings GL, (2007) Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 34: 255-262.
3. Chung E, Yeung F, Leinwand LA, (2012) Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation. J Appl Physiol 112: 1565-1575.
4. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, et al. (2006) Akt1 is required for physiological cardiac growth. Circulation 113: 2097-2104.
5. Eghbali M, Deva R, Alioua A, Minosyan TY, Ruan H, et al. (2005) Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 96: 1208-1216.
6. Heineke J, Molkentin JD, (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600.
7. Galindo C, Skinner M, Errami M, Olson LD, Watson D, et al. (2009) Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure. BMC Physiology 9: 23.
8. Ho TH, Charlet-B N, Poulos MG, Singh G, Swanson MS, et al. (2004) Muscleblind proteins regulate alternative splicing. Embo J 23: 3103-3112.
9. Czubryt MP, Olson EN, (2004) Balancing contractility and energy production: the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy. Recent Prog Horm Res 59: 105-124.
10. Barrick CJ, Rojas M, Schoonhoven R, Smyth SS, Threadgill DW, (2007) Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 292: H2119-H2130.
11. Strom CC, Aplin M, Ploug T, Christoffersen TEH, Langfort J, et al. (2005) Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 272: 2684-2695.
12. Bisping E, Ikeda S, Sedej M, Wakula P, McMullen JR, et al. (2012) Transcription factor GATA4 is activated but not required for insulin like growth factor 1-induced cardiac hypertrophy. J Biol Chem 287: 9827-9834.
13. Sanbe A, Gulick J, Hayes E, Warshaw D, Osinska H, et al. (2000) Myosin light chain replacement in the heart. Am J Physiol Heart Circ Physiol 279: H1355-1364.
14. Morano M, Zacharzowski U, Maier M, Lange PE, Alexi-Meskishvili V, et al. (1996) Regulation of human heart contractility by essential myosin light chain isoforms. J Clin Invest 98: 467-473.
15. Stilli D, Bocchi L, Berni R, Zaniboni M, Cacciani F, et al. (2006) Correlation of α-skeletal actin expression, ventricular fibrosis and heart function with the degree of pressure overload cardiac hypertrophy in rats. Experimental Physiology 91: 571-580.
16. Graham HK, Horn M, Trafford AW, (2008) Extracellular matrix profiles in the progression to heart failure. Acta Physiologica 194: 3-21.
17. Vanhoutte D, Heymans S, (2010) TIMPs and cardiac remodeling: Embracing the MMP-independent-side of the family. J Mol Cell Cardiol 48: 445-453.
18. Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, et al. (2008) Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodeling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 10: 133-139.
19. Mori S, Gibson G, McTiernan CF, (2006) Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model. J Card Fail 12: 314-325.
20. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, et al. (2005) Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112: 1136-1144.
21. Creemers EEJM, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, et al. (2003) Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284: H364-H371.
22. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, et al. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11: 1096-1103.
23. Kong SW, Bodyak N, Yue P, Liu Z, Brown J, et al. (2005) Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics 21: 34-42.
24. Kang PM, Izumo S, (2000) Apoptosis and heart failure: a critical review of the literature. Circ Res 86: 1107-1113.
25. Siu PM, Bryner RW, Martyn JK, Alway SE, (2004) Apoptotic adaptations from exercise training in skeletal and cardiac muscles. FASEB J 18: 1150-1152.
26. Galban S, Duckett CS, (2009) XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ 17: 54-60.
27. Aharinejad S, Andrukhova O, Lucas T, Zuckermann A, Wieselthaler G, et al. (2008) Programmed Cell Death in Idiopathic Dilated Cardiomyopathy is Mediated by Suppression of the Apoptosis Inhibitor Apollon. Ann Thorac Surg 86: 109-114.
28. Siu PM, Bryner RW, Murlasits Z, Alway SE, (2005) Response of XIAP, ARC, and FLIP apoptotic suppressors to 8 wk of treadmill running in rat heart and skeletal muscle. J Appl Physiol 99: 204-209.
29. Kang PM, Yue P, Liu Z, Tarnavski O, Bodyak N, et al. (2004) Alterations in apoptosis regulatory factors during hypertrophy and heart failure. Am J Physiol Heart Circ Physiol 287: H72-80.
30. Vaughan-Jones RD, Spitzer KW, Swietach P, (2009) Intracellular pH regulation in heart. J Mol Cell Cardiol 46: 318-331.
31. Isensee J, Witt H, Pregla R, Hetzer R, Regitz-Zagrosek V, et al. (2008) Sexually dimorphic gene expression in the heart of mice and men. J Mol Med 86: 61-74.
32. Kilic A, Javadov S, Karmazyn M, (2009) Estrogen exerts concentration-dependent pro-and anti-hypertrophic effects on adult cultured ventricular myocytes. Role of NHE-1 in estrogen-induced hypertrophy. J Mol Cell Cardiol 46: 360-369.
33. RÄISÄNEN SR, Lehenkari P, Tasanen M, Rahkila P, HÄRKÖNEN PL, et al. (1999) Carbonic anhydrase III protects cells from hydrogen peroxide-induced apoptosis. FASEB J 13: 513-522.
34. Kang YJ, (1999) The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med 222: 263-273.
35. Ye G, Metreveli NS, Ren J, Epstein PN, (2003) Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 52: 777-783.
36. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, et al. (2007) A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128: 589-600.
37. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, et al. (2010) B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 56: 1247-1253.
38. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, et al. (2001) Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 107: 975-984.
39. Lezoualc'h F, Métrich M, Hmitou I, Duquesnes N, Morel E, (2008) Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 44: 623-632.
40. Boström P, Mann N, Wu J, Quintero PA, Plovie ER, et al. (2010) C/EBP[beta] controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143: 1072-1083.
41. Jääskeläinen T, Makkonen H, Palvimo JJ, (2011) Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol 11: 326-331.
42. Weinberg EO, Mirotsou M, Gannon J, Dzau VJ, Lee RT, et al. (2003) Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics 12: 113-127.
43. Hubler TR, Denny WB, Valentine DL, Cheung-Flynn J, Smith DF, et al. (2003) The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology 144: 2380-2387.
44. Li HH, Kedar V, Zhang C, McDonough H, Arya R, et al. (2004) Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 114: 1058-1071.
45. Weeks KL, McMullen JR, (2011) The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology (Bethesda) 26: 97-105.
46. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, et al. (2001) Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. Embo J 20: 2757-2767.
47. Bueno OF, Molkentin JD, (2002) Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Cir Res 91: 776-781.
48. Dong H, Yauk CL, Williams A, Lee A, Douglas GR, et al. (2007) Hepatic Gene Expression Changes in Hypothyroid Juvenile Mice: Characterization of a Novel Negative Thyroid-Responsive Element. Endocrinology 148: 3932-3940.
49. Zordoky BNM, Anwar-Mohamed A, Aboutabl ME, El-Kadi AOS, (2010) Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242: 38-46.
50. Tsuchiya Y, Nakajima M, Yokoi T, (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Letters 227: 115-124.
51. Thum T, Borlak J, (2002) Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16: 1537-1549.
52. Zordoky BNM, Aboutabl ME, El-Kadi AOS, (2008) Modulation of Cytochrome P450 Gene Expression and Arachidonic Acid Metabolism during Isoproterenol-Induced Cardiac Hypertrophy in Rats. Drug Metab Dispos 36: 2277-2286.
53. Elbekai RH, El-Kadi AOS, (2006) Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacol Ther 112: 564-587.
54. Chaudhary KR, Batchu SN, Seubert JM, (2009) Cytochrome P450 enzymes and the heart. IUBMB Life 61: 954-960.
55. Dubey RK, Jackson EK, Gillespie DG, Rosselli M, Barchiesi F, et al. (2005) Cytochromes 1A1/1B1- and Catechol-O-Methyltransferase-Derived Metabolites Mediate Estradiol-Induced Antimitogenesis in Human Cardiac Fibroblast. J Clin Endocrinol Metab 90: 247-255.
56. Dubey RK, Gillespie DG, Jackson EK, Keller PJ, (1998) 17beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 31: 522-528.
57. Simoncini T, Maffei S, Basta G, Barsacchi G, Genazzani AR, et al. (2000) Estrogens and Glucocorticoids Inhibit Endothelial Vascular Cell Adhesion Molecule-1 Expression by Different Transcriptional Mechanisms. Cir Res 87: 19-25.
58. Reid MB, (2005) Response of the ubiquitin-proteasome pathway to changes in muscle activity. Am J Physiol Regul Integr Comp Physiol 288: R1423-R1431.
59. Glass DJ, (2003) Signaling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 5: 87-90.
60. Razeghi P, Sharma S, Ying J, Li Y-P, Stepkowski S, et al. (2003) Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 108: 2536-2541.
61. Hedhli N, Depre C, (2010) Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 85: 321-329.
62. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, et al. (2008) Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol 295: H1385-H1393.
63. Allen DL, Harrison BC, Maass A, Bell ML, Byrnes WC, et al. (2001) Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J Appl Physiol 90: 1900-1908.
64. Luckey SW, Walker LA, Smyth T, Mansoori J, Messmer-Kratzsch A, et al. (2009) The role of Akt/GSK-3[beta] signaling in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 46: 739-747.
65. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
66. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F (2004) A model based background adjustment for oligonucleotide expression arrays. pp. Johns Hopkins University, Department of Biostatistics Working papers, working paper 1,.
67. Baldi P, Long AD, (2001) A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17: 509-519.
68. Choe S, Boutros M, Michelson A, Church G, Halfon M, (2005) Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol 6: R16.
69. Vardhanabhuti S, Blakemore SJ, Clark SM, Ghosh S, Stephens RJ, et al. (2008) A comparison of statistical tests for detecting differential expression using Affymetrix oligonucleotide microarrays. OMICS 10: 555-566.
70. Huang DW, Sherman BT, Lempicki RA, (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 4: 44-57.
71. Konhilas JP, Watson PA, Maass A, Boucek DM, Horn T, et al. (2006) Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res 98: 540-548.
72. Powell SR, Davies KJA, Divald A, (2007) Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrations. J Mol Cell Cardiol 42: 265-269.